CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 315 enrolled
Drug / intervention
rosuvastatin calcium +2 moredrug
Likely dose
rosuvastatin calcium 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01078675
NCT01078675Phase 3Completed

An Efficacy and 2-Year Safety Study of Open-label Rosuvastatin in Children and Adolescents (Aged From 6 to Less Than 18 Years) With Familial Hypercholesterolaemia

AstraZeneca·interventional·Posted Mar 2, 2010·Updated Apr 7, 2015

In Brief

A Phase 3 clinical trial evaluating rosuvastatin calcium for Familial Hypercholesterolaemia. Completed, enrolled 315 participants across 15 sites in 5 countries.

Detailed Summary

This study is being carried out to see if the study medication, rosuvastatin, is effective in treating familial hypercholesterolaemia in children and adolescents, and to determine the long term (over 2 years) safety, tolerability and efficacy of the study medication in these patients. This study will also measure levels of drug in the blood and see how well it is tolerated. This is known as pharmacokinetic (PK) analysis. At baseline only a small number of patients will participate in a single dose PK phase over 24 hours. In order to see if this medication works, a control group of healthy siblings will help the researchers to compare certain results.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Canada, Netherlands, Norway, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2, 2010
Enrollment StartFeb 1, 2010
Primary CompletionFeb 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 16.3 years ago

Interventions

rosuvastatin calciumdrug

5 mg, oral, once daily, 24 months

rosuvastatin calciumdrug

10 mg, oral, once daily, 24 months

rosuvastatin calciumdrug

20 mg, oral, once daily, 24 months